tiprankstipranks
Compass Therapeutics, Inc. (CMPX)
NASDAQ:CMPX
US Market
CMPX
Compass Therapeutics
RESEARCH TOOLSreports
Want to see CMPX full AI Analyst Report?

Compass Therapeutics (CMPX) Stock News & Sentiment

558 Followers
Compass Therapeutics Adopts Second Amended and Restated Bylaws
Premium
Company Announcements
Compass Therapeutics Adopts Second Amended and Restated Bylaws
2d ago
8K
CMPX
Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight
Premium
Company Announcements
Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight
13d ago
8K
CMPX
Compass Therapeutics Maintained at Buy as Analyst Cites Promising CTX-8371 Data and Reaffirms $24 Price Target
Premium
Ratings
Compass Therapeutics Maintained at Buy as Analyst Cites Promising CTX-8371 Data and Reaffirms $24 Price Target
1M ago
CMPX
Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
Premium
Ratings
Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
2M ago
CMPX
Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
Premium
Ratings
Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
2M ago
CMPX
Buy Rating Reiterated on Compass Therapeutics as Tovecimig Combo Shows Strong PFS Benefit but OS Signal Clouded by Crossover Effects
Premium
Ratings
Buy Rating Reiterated on Compass Therapeutics as Tovecimig Combo Shows Strong PFS Benefit but OS Signal Clouded by Crossover Effects
2M ago
CMPX
Compass Therapeutics Reports Positive Phase 2/3 BTC Results
Premium
Company Announcements
Compass Therapeutics Reports Positive Phase 2/3 BTC Results
2M ago
8K
CMPX
More CMPX News >

CMPX News on the Web

Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight
TipRanks News
Neutral
Compass Therapeutics Inc. Annual Shareholders Meeting Transcript
GuruFocus News
Neutral
Compass Therapeutics Inc. at Goldman Sachs Healthcare Conference Transcript
GuruFocus News
Neutral
Compass Therapeutics To Present Phase 1 Data Results Of CTX-8371 At ASCO 2026
rttnews
Bullish
Canaccord Genuity Sticks to Their Buy Rating for Compass Therapeutics (CMPX)
TipRanks News
Bullish
Compass Therapeutics Maintained at Buy as Analyst Cites Promising CTX-8371 Data and Reaffirms $24 Price Target
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Guardant Health (GH) and Compass Therapeutics (CMPX)
TipRanks News
Neutral
Compass Therapeutics (CMPX): Favorable Risk‑Reward Ahead of Pivotal Tovecimig Data in Biliary Tract Cancer
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
CMPX
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.75 articles
News Sentiment
This Week50%
Sector Average90%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CMPX’s Media Buzz Sentiment?
1 articles about CMPX were published this week. In an average week, 1.75 articles are published.
    What is CMPX’s weekly average amount of articles?
    In an average week, 1.75 articles about CMPX are published.
      What is CMPX’s News Sentiment?
      50% of articles about CMPX were positive this week, compared to its sector average of 90%.
        Healthcare Stocks that are Trending in the News
        DFTXDefinium Therapeutics
        ABBVAbbVie, Inc. CDR (CAD Hedged)
        APGEApogee Therapeutics
        MLTXMoonLake Immunotherapeutics
        ABBVAbbVie
        Showing the stocks with the most bullish news sentiment over the past week